SCHEDULE: Investment Entities Disclose 9.9% Stake in Pelthos Therapeutics Following Reverse Stock Split

3i, LP, 3i Management LLC, and Maier Joshua Tarlow have disclosed a 9.9% beneficial ownership stake in Pelthos Therapeutics Inc., holding 303,138 shares of common stock after the company's 1-for-10 reverse stock split.

Summary

• 3i, LP, 3i Management LLC, and Maier Joshua Tarlow (collectively, "Reporting Persons") have filed a Schedule 13G disclosing their beneficial ownership in Pelthos Therapeutics Inc.
• The Reporting Persons collectively own 303,138 shares of Pelthos Therapeutics Inc. common stock, representing 9.9% of the outstanding class.
• This ownership percentage is based on 3,034,416 shares of common stock outstanding as of July 7, 2025.
• The reported share numbers reflect a 1-for-10 reverse stock split of Pelthos Therapeutics Inc.'s common stock, which was effective on July 1, 2025.
• The Reporting Persons hold 300,000 shares of common stock directly and additional shares issuable upon full conversion of 2,000 shares of Series A Convertible Preferred Stock.
• Conversion of the Preferred Stock is subject to a 9.99% beneficial ownership blocker, preventing the Reporting Persons from exceeding this threshold.
• The acquisition of these securities was not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects. The sentiment is neutral.

Risks

• The Reporting Persons' ability to fully convert their Series A Convertible Preferred Stock into common stock is limited by a 9.99% beneficial ownership blocker, preventing them from exceeding this ownership threshold.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a standard disclosure of significant beneficial ownership, indicating an investment entity's substantial stake in Pelthos Therapeutics Inc. It does not provide broader industry trends or competitive analysis, but rather focuses on the ownership structure of a single company within its sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.9% stake by an investment group could be viewed as a vote of confidence or a potential influence on future corporate actions, impacting existing shareholders.

Key Dates

Keywords

Pelthos Therapeutics Inc., Schedule 13G, Beneficial Ownership, Common Stock, Reverse Stock Split, 3i LP, 3i Management LLC, Maier Joshua Tarlow, Preferred Stock, Ownership Blocker